Evidence map›Paper›PMID 40454418›Full record

ArticleMolecular therapy. Methods & clinical development2025

Harnessing synaptic vesicle release and recycling with antibody shuttle for targeted delivery of therapeutics to neurons.

Karen Kar Lye Yee, Junichi Kumamoto, Daijiro Inomata, Naoki Suzuki, Ryuhei Harada, Norihiro Yumoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Karen Kar Lye YeeJiksak Bioengineering, Inc., Cybernics Medical Innovation Base-A room 322, 3-25-16 Tonomachi, Kawasaki-ku Kawasaki-shi, Kanagawa 210-0821, Japan.
Junichi KumamotoJiksak Bioengineering, Inc., Cybernics Medical Innovation Base-A room 322, 3-25-16 Tonomachi, Kawasaki-ku Kawasaki-shi, Kanagawa 210-0821, Japan.
Daijiro InomataJiksak Bioengineering, Inc., Cybernics Medical Innovation Base-A room 322, 3-25-16 Tonomachi, Kawasaki-ku Kawasaki-shi, Kanagawa 210-0821, Japan.
Naoki SuzukiDepartment of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku Sendai, Miyagi 980-8574, Japan.
Ryuhei HaradaDepartment of Neurology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku Sendai, Miyagi 980-8574, Japan.
Norihiro YumotoJiksak Bioengineering, Inc., Cybernics Medical Innovation Base-A room 322, 3-25-16 Tonomachi, Kawasaki-ku Kawasaki-shi, Kanagawa 210-0821, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effective delivery of therapeutic molecules to neurons are mainly limited by the presence of the blood-brain barrier (BBB) and blood-spinal cord barrier (BSCB), leading to suboptimal therapeutic outcomes in neurodegenerative diseases treatment. This study introduces a neuron-selective drug delivery system that utilizes the synaptic vesicle release and recycling mechanism (SVRM) to overcome these barriers. This delivery system consists of an antibody shuttle that targets SV transmembrane proteins, which enables selective molecule delivery to neurons. We demonstrated that intravenously administered antibodies raised against the luminal domain of synaptotagmin-2 (SYT2) selectively localize to neuromuscular junctions. They were taken up and retrogradely transported to CHAT-positive motor neurons in both the spinal cord and brainstem. Anti-SYT2 antibody delivery of anti-microtubule agent and

Indexed as

blood brain barrierblood spinal cord barrierdrug delivery systemintravenous administrationmonoclonal antibody shuttlemotor neuronsneuromuscular junctionpre-synapsesynaptic vesicle transmembrane luminal domainsystemic administration

Identifiers

PMID40454418
PMCPMC12124621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.